Course – Biosimilars and Oncology:
A Virtual Roundtable
Course Description “Biosimilars in Oncology: A Virtual Roundtable”
This program is an audio archive of an expert virtual roundtable on biosimilars in oncology, bringing experts together in a live digital forum to share their knowledge and perspectives on emerging biosimilars in oncology for an actively engaged online audience. Topics of discussion will include interchangeability of biosimilars for reference biologics, safety and efficacy data from available clinical trials, advantages and disadvantages of biosimilar use in oncology, federal and state guidance around the use of biosimilars, and clinician perceptions and practices in biosimilars use in oncology. An infographic is available to accompany the content of the audio archive.
Upon completion of this program, clinicians will be able to:
- Explain the interchangeability of biosimilars for reference biologics
- Discuss clinician perceptions and practices for biosimilar use in oncology
- Identify federal and state guidance around the use of biosimilars
- Describe the advantages and disadvantages of biosimilar use
- Examine safety and efficacy data from available clinical trials
Oncologists, primary care physicians, and clinicians who manage patients with cancer.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of New York Medical College and the Angiogenesis Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.
New York Medical College designates this Enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All activity faculty and planners participating in continuing medical education activities provided by New York Medical College are expected to disclose to the audience any significant support or substantial relationship(s) with commercial entities whose products are discussed in their presentation and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentations.
William Li, MD
Dr. Li has nothing to disclose with regard to commercial interests.
Clifford Goodman, PhD
Dr. Goodman is an employee of The Lewin Group, a business unit of Optum, which is a subsidiary of UnitedHealth Group. He also owns stock in UnitedHealth Group.
Jeffrey Crawford, MD
Dr. Crawford is a scientific advisor for Merck, Novartis, and Pfizer. He is a DSMB member for Celgene, G1 Therapeutics, Jannsen, Merrimack, and Roche. He receives grant/research support from Amgen, AstraZeneca, Bayer, Clovis, Genentech, and GTx.
Philip Lammers, MD, MSCI
Dr. Lammers serves as a consultant to Pfizer
Jeffrey McRae, MS
The Angiogenesis Foundation
Mr. McRae has nothing to disclose with regard to commercial interests.
Commercial Support Acknowledgement:
We gratefully acknowledge Pfizer for their generous support of this educational activity.
Instructions for Participation and Credit:
There are no fees for participating in or receiving credit for this online educational activity.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit:
• Read the objectives, audience, and disclosure statements
• Review the Infographic
• Listen to the audio segments or read the full transcript
• Complete the Course Quiz, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
Release and Expiration
Date of original release: December 17, 2017
Date of expiration: December 17, 2018